FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA's acceptance of Roche's NDA for giredestrant marks a pivotal moment in breast cancer treatment, potentially establishing a new standard of care. This advancement not only enhances Roche's competitive positioning but also addresses a significant unmet need in early-stage ER-positive breast cancer management.

The FDA's acceptance of Roche's NDA for giredestrant marks a pivotal moment in breast cancer treatment, potentially establishing a new standard of care. This advancement not only enhances Roche's competitive positioning but also addresses a significant unmet need in early-stage ER-positive breast cancer management.

Regulatory Approval

The FDA has accepted Roche's NDA for giredestrant, an oral SERD, under priority review based on phase III data showing a 30% reduction in invasive disease recurrence or death compared to standard therapy.

The FDA's acceptance of Roche's NDA for giredestrant marks a pivotal moment in breast cancer treatment, potentially establishing a new standard of care. This advancement not only enhances Roche's competitive positioning but also addresses a significant unmet need in early-stage ER-positive breast cancer management.

Monitor the FDA's decision on giredestrant's approval by November 30, 2026, and ongoing results from the lidERA study regarding overall survival data.